Clovis Oncology Inc : * Acquires EOS (Ethical Oncology Science) S.P.A. to gain rights to Lucitanib, a unique dual-selective phase II FGFR/VEGFR inhibitor * Says buying eos for up-front payment of $200 million, which includes $190million in Clovis common stock and $10 million in cash * Says will pay an additional $65 million in cash upon initial approval ofLucitanib by U.S. food and drug association * Says co and Servier will collaborate on development of lucitanib pursuant toa mutually-agreed upon global development plan * Source text for Eikon * Further company coverage
Clovis Oncology, Inc. is a United States-based biopharmaceutical company. Shares of CLVS fell by 3.27% or $-1.58/share to $46.76. In the past year, the shares have traded as low as $11.67 and as high as $86.29. On average, 441051 shares of CLVS exchange hands on a given day and today's volume is recorded at 214746.
Source
